DOI QR코드

DOI QR Code

Implications of Emphysema and Lung Function for the Development of Pneumonia in Patients with Chronic Obstructive Pulmonary Disease

  • Hong, Yoonki (Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University College of Medicine) ;
  • Lee, Jae Seung (Department of Pulmonary and Critical Care Medicine and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Yoo, Kwang Ha (Department of Internal Medicine, Konkuk University School of Medicine) ;
  • Lee, Ji-Hyun (Department of Internal Medicine, CHA Bundang Medical Center, CHA University) ;
  • Kim, Woo Jin (Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University College of Medicine) ;
  • Lim, Seong Yong (Division of Pulmonary and Critical Care Medicine, Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Rhee, Chin Kook (Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Lee, Sang-Do (Department of Pulmonary and Critical Care Medicine and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Oh, Yeon-Mok (Department of Pulmonary and Critical Care Medicine and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2015.11.04
  • Accepted : 2015.12.28
  • Published : 2016.03.31

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is sometimes complicated with pneumonia, but little is known about the risk factors that promote the development of pneumonia in COPD. These risk factors were evaluated in the present study. Methods: The data of 324 patients with COPD from a prospective multi-center observational cohort with obstructive lung disease were evaluated retrospectively. To identify risk factors for the development of pneumonia in COPD, the clinical and radiological data at enrollment and the time to the first episode of pneumonia were analyzed by Cox proportional hazard analysis. Results: The median follow-up time was 1,099 days and 28 patients (8.6%) developed pneumonia. The Cox analysis showed that post-bronchodilator forced expiratory volume in one second ($FEV_1$, % of predicted) and the computed tomography (CT) emphysema extent (inspiratory V950) were independent risk factors for the development of pneumonia (post-bronchodilator $FEV_1$: hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.94-1.00; p=0.048 and inspiratory V950: HR, 1.04; 95% CI, 1.01-1.07; p=0.01). Conclusion: Emphysema severity measured by CT and post-bronchodilator $FEV_1$ are important risk factors for the development of pneumonia in COPD.

Keywords

References

  1. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;182:598-604. https://doi.org/10.1164/rccm.200912-1843CC
  2. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-73. https://doi.org/10.1016/S0140-6736(07)61380-4
  3. Centers for Disease Control and Prevention (CDC). Pneumonia and influenza death rates: United States, 1979-1994. MMWR Morb Mortal Wkly Rep 1995;44:535-7.
  4. Falguera M, Martin M, Ruiz-Gonzalez A, Pifarre R, Garcia M. Community-acquired pneumonia as the initial manifestation of serious underlying diseases. Am J Med 2005;118:378-83. https://doi.org/10.1016/j.amjmed.2005.01.011
  5. Mannino DM, Davis KJ, Kiri VA. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir Med 2009;103:224-9. https://doi.org/10.1016/j.rmed.2008.09.005
  6. Molinos L, Clemente MG, Miranda B, Alvarez C, del Busto B, Cocina BR, et al. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect 2009;58:417-24. https://doi.org/10.1016/j.jinf.2009.03.003
  7. Pifarre R, Falguera M, Vicente-de-Vera C, Nogues A. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med 2007;101: 2139-44. https://doi.org/10.1016/j.rmed.2007.05.011
  8. Calverley PM, Stockley RA, Seemungal TA, Hagan G, Willits LR, Riley JH, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011;139:505-12. https://doi.org/10.1378/chest.09-2992
  9. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89. https://doi.org/10.1056/NEJMoa063070
  10. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and metaanalysis. JAMA 2008;300:2407-16. https://doi.org/10.1001/jama.2008.717
  11. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169: 219-29. https://doi.org/10.1001/archinternmed.2008.550
  12. Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology 2011;261:274-82. https://doi.org/10.1148/radiol.11110173
  13. Kim WJ, Oh YM, Sung J, Lee YK, Seo JB, Kim N, et al. CT scanning-based phenotypes vary with ADRB2 polymorphisms in chronic obstructive pulmonary disease. Respir Med 2009;103: 98-103. https://doi.org/10.1016/j.rmed.2008.07.025
  14. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003;348:2059-73. https://doi.org/10.1056/NEJMoa030287
  15. Kim WJ, Oh YM, Sung J, Kim TH, Huh JW, Jung H, et al. Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung 2008;186:381-6. https://doi.org/10.1007/s00408-008-9103-9
  16. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676-82. https://doi.org/10.1093/aje/kwq433
  17. Lee YK, Oh YM, Lee JH, Kim EK, Lee JH, Kim N, et al. Quantitative assessment of emphysema, air trapping, and airway thickening on computed tomography. Lung 2008;186:157-65. https://doi.org/10.1007/s00408-008-9071-0
  18. Almirall J, Bolibar I, Serra-Prat M, Palomera E, Roig J, Hospital I, et al. Relationship between the use of inhaled steroids for chronic respiratory diseases and early outcomes in community-acquired pneumonia. PLoS One 2013;8:e73271. https://doi.org/10.1371/journal.pone.0073271
  19. Eom JS, Song WJ, Yoo H, Jeong BH, Lee HY, Koh WJ, et al. Chronic obstructive pulmonary disease severity is associated with severe pneumonia. Ann Thorac Med 2015;10:105-11. https://doi.org/10.4103/1817-1737.151441
  20. Han MK, Bartholmai B, Liu LX, Murray S, Curtis JL, Sciurba FC, et al. Clinical significance of radiologic characterizations in COPD. COPD 2009;6:459-67. https://doi.org/10.3109/15412550903341513
  21. Martinez FJ, Foster G, Curtis JL, Criner G, Weinmann G, Fishman A, et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 2006;173:1326-34. https://doi.org/10.1164/rccm.200510-1677OC
  22. Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest 2011;140:626-33. https://doi.org/10.1378/chest.10-2948

Cited by

  1. Clinical relevance of emphysema in patients hospitalized with community‐acquired pneumonia: Clinical features and prognosis vol.15, pp.7, 2021, https://doi.org/10.1111/crj.13370